Oncimmune Holdings plc (OCY.SG)

0.2420 -0.0020 (-0.82%) 市場開市。 截至 08:08AM CEST。

Oncimmune Holdings plc

1 Park Row
Leeds LS1 5AB
United Kingdom

https://www.oncimmune.com

版塊: Healthcare
行業: Biotechnology
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Martin John Gouldstone	CEO & Director	無	無	1966
Mr. Martin Hudson	Finance Director	無	無	無
Mr. Ron Kirschner	COO, General Counsel & Company Secretary	無	無	1979
Prof. Tariq Sethi B.Sc., FRCP, M.A., M.D., Ph.D.	Chief Scientific Officer	無	無	無
Ms. Cléa Rosenfeld	Head of Investor Relations	無	無	無
Mr. Maarten Brusse	Chief Commercial Officer of Asia	無	無	無

截止 為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 EUR。

描述

Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Leeds, the United Kingdom.

公司管治

截至 無 止，Oncimmune Holdings plc 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。